AXITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H18N4OS
Molecular Weight	386.47
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(\C=C\C4=CC=CC=N4)=NN3

InChI

InChIKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N

InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+

HIDE SMILES / InChI

Molecular Formula	C22H18N4OS
Molecular Weight	386.47
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.drugdevelopment-technology.com/projects/axitinib-carcinoma/; http://www.ncbi.nlm.nih.gov/pubmed/18541897; https://www.ncbi.nlm.nih.gov/pubmed/?term=19010843

Axitinib (trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. It was approved by the U.S. Food and Drug Administration.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Vascular endothelial growth factor receptor 1 40 Target ID: P17948\|\|\|B3FR89 Gene ID: 2321.0 Gene Symbol: FLT1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=19010843	Inhibitor 8228	0.1 nM [IC50]
Vascular endothelial growth factor receptor 2 102 Target ID: P35968 Gene ID: 3791.0 Gene Symbol: KDR Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=19010843	Inhibitor 8228	0.2 nM [IC50]
Vascular endothelial growth factor receptor 3 40 Target ID: P35916 Gene ID: 2324.0 Gene Symbol: FLT4 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=19010843	Inhibitor 8228	0.3 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Renal cell carcinoma 30 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	Secondary		Approved 8360	INLYTA Approved Use Indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Launch Date 1.32762239E12

C_max

Value	Dose	Analyte	Population
32.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
28.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
52.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
51.1 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19603168	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
162 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
27.8 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
27.8 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg 2 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

AUC

Value	Dose	Analyte	Population
160.3 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
162 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
206.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
187 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19603168	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2171 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
265 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
717 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
265 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg 2 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

T_1/2

Value	Dose	Analyte	Population
5.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22644797	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19603168	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AXITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
4.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16027439	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		AXITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	5 mg 2 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AXITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

Doses

Dose	Population	Adverse events
5 mg 2 times / day steady, oral (starting) Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000MedR.pdf	unhealthy, 62 years (range: 20-82 years) n = 359 Health Status: unhealthy Age Group: 62 years (range: 20-82 years) Sex: M+F Population Size: 359 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000MedR.pdf	Disc. AE: Disease progression, Fatigue... AEs leading to discontinuation/dose reduction: Disease progression (11 patient) Fatigue (4 patients) Transient ischemic attack (3 patients) Asthenia (2 patients) Pleural effusion (2 patients) Decreased appetite (2 patients) Palmar-plantar erythrodysaesthesia syndrome (1 patient) Dyspnea (1 patient) Anemia (1 patient) Vomiting (1 patient) Retinal vein thrombosis (1 patient) Ascites (1 patient) Blood creatinine increased (1 patient) Hypoglycemia (1 patient) Altered state of consciousness (1 patient) Cerebral hemorrhage (1 patient) Dyspnea exertional (1 patient) Pneumothorax (1 patient) Hypertension (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000MedR.pdf
30 mg 2 times / day steady, oral Highest studied dose Dose: 30 mg, 2 times / day Route: oral Route: steady Dose: 30 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	unhealthy n = 2 Health Status: unhealthy Condition: advanced solid malignancies Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	Sources: https://pubmed.ncbi.nlm.nih.gov/16027439
5 mg 2 times / day steady, oral MTD Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	unhealthy n = 8 Health Status: unhealthy Condition: advanced solid malignancies Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	DLT: Stomatitis... Dose limiting toxicities: Stomatitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16027439
15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	unhealthy n = 6 Health Status: unhealthy Condition: advanced solid malignancies Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	DLT: Hypertension, Stomatitis... Dose limiting toxicities: Hypertension (1 patient) Stomatitis (1 patient) Pancreatitis (1 patient) Bowel ischemia (1 patient) Thromboembolism (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16027439
20 mg 2 times / day steady, oral Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	unhealthy n = 4 Health Status: unhealthy Condition: advanced solid malignancies Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/16027439	DLT: Hypertension, Hemoptysis... Dose limiting toxicities: Hypertension (2 patients) Hemoptysis (1 patient) Stomatitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16027439

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579 inducer 768	inhibitor 1752	inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2A6 704 CYP2C8 901 CYP2C19 1463 CYP2E1 876 P-gp 1437 UGT1A1 204	CYP3A5 391 CYP1A2 1032 CYP2C19 985 UGT1A1 418 P-gp 1527 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 290 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213 BCRP 555 OATP1B1 403 OATP1B3 347	CYP1A 56

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A 121	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
CYP2A6 736	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
CYP3A4 1909	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A1 254	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes [IC50 4.5 uM]
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes [Ki 0.5 uM]	no (co-administration study) Comment: axitinib has no effect on exposure of paclitaxel Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes [Ki 0.7 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes [Ki 52.2 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes [Ki 8.3 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	major	yes (co-administration study) Comment: ketoconazole increased cmax of axitinib by by 50%, auc by 106% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf
CYP3A5 391	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	major	yes (co-administration study) Comment: ketoconazole increased cmax of axitinib by by 50%, auc by 106% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	minor
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	minor	no (pharmacogenomic study) Comment: no clinical effect was observed in genotyping study Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf
UGT1A1 418	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	minor	no (pharmacogenomic study) Comment: no clinical effect was observed in genotyping study Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf
UGT1A10 290	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A3 422	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A4 347	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A6 307	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A7 236	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A8 283	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT1A9 380	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT2B15 203	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT2B17 213	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT2B4 249	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
UGT2B7 389	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	no
BCRP 555	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes
OATP1B1 403	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes
OATP1B3 347	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes
P-gp 1527	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000PharmR.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:66910	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:66910
ChemicalBook	CB81011728	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB81011728
MolPort	MolPort-006-392-413	https://www.molport.com/shop/molecule-link/MolPort-006-392-413
Selleck Chemicals	Axitinib	http://www.selleckchem.com/products/Axitinib.html
ZINC	ZINC000003816287	http://zinc15.docking.org/substances/ZINC000003816287
eMolecules	26951384	https://www.emolecules.com/cgi-bin/more?vid=26951384

PubMed

Title	Date	PubMed
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.	2009 Sep 20	19652060
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.	2010 Nov	20869793
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	2010 Nov 24	21095574
Comprehensive analysis of kinase inhibitor selectivity.	2011 Oct 30	22037378
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.	2015 Nov	26259608

Patents

Sample Use Guides

In Vivo Use Guide

5 mg orally twice daily

Route of Administration: Oral

In Vitro Use Guide

Transfected or endogenous RTK-expressing cells were treated by axitinib with range of concentration from 0.01 nM to 10 uM. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively. Cellular activity against VEGFR-1 was 1.2 nmol/L.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:45:58 UTC 2023` Edited by `admin` on `Wed Jul 05 23:45:58 UTC 2023`
Record UNII	C9LVQ0YUXG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AXITINIB

Official Name

English

N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE

Systematic Name

English

AXITINIB [VANDF]

Common Name

English

AG-013736

Code

English

AXITINIB [ORANGE BOOK]

Common Name

English

AXITINIB [MI]

Common Name

English

Axitinib [WHO-DD]

Common Name

English

axitinib [INN]

Common Name

English

NSC-757441

Code

English

AG-13736

Code

English

AXITINIB [MART.]

Common Name

English

BENZAMIDE, N-METHYL-2-((3-((1E)-2-(2-PYRIDINYL)ETHENYL)-1H-INDAZOL-6-YL)THIO)-

Systematic Name

English

AXITINIB [JAN]

Common Name

English

INLYTA

Brand Name

English

N-METHYL-2((3-((1E0-2-(PYRIDIN-2-YL)ETHENYL)-1H-INAZOL-6-YLSUFANYL)BENZAMIDE

Common Name

English

AXITINIB [USAN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01XE17